Rating Worth Mentioning: What To Expect From Imprimis Pharmaceuticals (IMMY) After Rodman & Renshaw’s New Coverage?

November 28, 2016 - By Dolores Ford

Rating Worth Mentioning: What To Expect From Imprimis Pharmaceuticals (IMMY) After Rodman & Renshaw's New Coverage?

Why Rodman & Renshaw Gives Imprimis Pharmaceuticals (IMMY) $5.0 Price Target

EU: Imprimis Pharmaceuticals (IMMY) coverage was was started with a “Buy” rating and $5.0 price target at Rodman & Renshaw. Rodman & Renshaw’s target price would indicate upside of 91.57% from the company’s current price.

The stock decreased 0.39% or $0.01 on November 25, hitting $2.54. Imprimis Pharmaceuticals Inc (IMMY) has declined 34.42% since April 25, 2016 and is downtrending. It has underperformed by 40.44% the S&P500.

Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on March, 22.

Insitutional Activity: The institutional sentiment increased to 5.5 in Q2 2016. Its up 4.30, from 1.2 in 2016Q1. The ratio is positive, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.

Northern Corporation holds 43,667 shares or 0% of its portfolio. Blackrock Investment Ltd Limited Liability Company owns 1,966 shares or 0% of their US portfolio. Tower Capital Lc (Trc) has 548 shares for 0% of their US portfolio. Moreover, Vanguard Grp has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 168,584 shares. Moreover, Bard has 0.13% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 65,500 shares. Opaleye Management accumulated 0.98% or 265,000 shares. Bancorp Of America De has invested 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Pnc Fincl Service Gp has invested 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Marathon Cap Management holds 0.05% or 25,000 shares in its portfolio. Manufacturers Life The holds 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 169 shares. Blackrock Fund Advsrs, a California-based fund reported 32,979 shares. Creative Planning accumulated 0% or 750 shares. Geode Cap Mgmt Ltd Limited Liability Company last reported 17,570 shares in the company. Marathon Asset Mgmt Ltd Partnership, a New York-based fund reported 833,333 shares. Granite Invest Partners Ltd Co holds 0.05% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 155,190 shares.

Imprimis Pharmaceuticals, Inc. is engaged in the development, production and dispensing of compounded pharmaceuticals. The company has a market cap of $34.32 million. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It currently has negative earnings. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”

IMMY Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.

More notable recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” on August 15, 2016, also Prnewswire.com with their article: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …” published on October 17, 2016, Prnewswire.com published: “Imprimis Pharmaceuticals Signs License Agreement to Bring Proprietary …” on August 12, 2015. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) were released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to …” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015” with publication date: October 20, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>